| Name | Title | Contact Details |
|---|
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built a discovery platform on our expertise across three major focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology. And we care. A lot. Patients are counting on us, and we`re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Through it all, we are propelled by our connections. We believe in our people to be…just who they are. We believe in our work and in each other – in enjoying this journey together so that we can achieve the Other Side of Possible.
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.
At Runatek, were ending the Opioid Crisis with innovative technology
Suncoast Pharmacy RX is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New Age Medical Center Functional Medicine plays a vital role in our everyday lives and Dr. Moreno is committed to helping our patients achieve improved overall wellness. In addition to internal medicine, anti-aging procedures, and nutritional & wei...